Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2011, Article ID 830260, 9 pages
http://dx.doi.org/10.1155/2011/830260
Review Article

Autophagic and Apoptotic Effects of HDAC Inhibitors on Cancer Cells

Department of Microbiology and Immunology, Tohoku University Graduate School of Dentistry, 4-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan

Received 23 June 2010; Accepted 3 March 2011

Academic Editor: Patrick Matthias

Copyright © 2011 Hidemi Rikiishi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [66 citations]

The following is the list of published articles that have cited the current article.

  • Omar Khan, and Nicholas B La Thangue, “HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications,” Immunology and Cell Biology, vol. 90, no. 1, pp. 85–94, 2011. View at Publisher · View at Google Scholar
  • Oliver Trüe, and Patrick Matthias, “Interplay between histone deacetylases and autophagy - from cancer therapy to neurodegeneration,” Immunology and Cell Biology, vol. 90, no. 1, pp. 78–84, 2011. View at Publisher · View at Google Scholar
  • Mário Songane, Johanneke Kleinnijenhuis, Mihai G. Netea, and Reinout Van Crevel, “The role of autophagy in host defence against Mycobacterium tuberculosis infection,” Tuberculosis, vol. 92, no. 5, pp. 388–396, 2012. View at Publisher · View at Google Scholar
  • Dingfeng Wu, Qi Huang, Yida Zhang, Qingchen Zhang, Qi Liu, Jun Gao, Zhiwei Cao, and Ruixin Zhu, “Screening of selective histone deacetylase inhibitors by proteochemometric modeling,” Bmc Bioinformatics, vol. 13, 2012. View at Publisher · View at Google Scholar
  • Pete Taylor, Jason Fangusaro, Veena Rajaram, Stewart Goldman, Irene B. Helenowski, Tobey MacDonald, Martin Hasselblatt, Lars Riedemann, Alvaro Laureano, Laurence Cooper, and Vidya Gopalakrishnan, “REST Is a Novel Prognostic Factor and Therapeutic Target for Medulloblastoma,” Molecular Cancer Therapeutics, vol. 11, no. 8, pp. 1713–1723, 2012. View at Publisher · View at Google Scholar
  • Carmen Sanmartín, Daniel Plano, Arun K. Sharma, and Juan Antonio Palop, “Selenium compounds, apoptosis and other types of cell death: An overview for cancer therapy,” International Journal of Molecular Sciences, vol. 13, no. 8, pp. 9649–9672, 2012. View at Publisher · View at Google Scholar
  • Syed F Zafar, Ganji Purnachandra Nagaraju, and Bassel El-Rayes, “Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma,” Expert Opinion on Therapeutic Targets, vol. 16, no. 7, pp. 707–718, 2012. View at Publisher · View at Google Scholar
  • Shan-Qi Guo, and Yi-Zhuo Zhang, “Histone deacetylase inhibition: an important mechanism in the treatment of lymphoma,” Cancer Biology and Medicine, vol. 9, no. 2, pp. 85–89, 2012. View at Publisher · View at Google Scholar
  • Alexander Dewerth, Timo Wonner, Justus Lieber, Verena Ellerkamp, Steven W. Warmann, Joerg Fuchs, and Sorin Armeanu-Ebinger, “In vitro evaluation of the Aurora kinase inhibitor VX-680 for Hepatoblastoma,” Pediatric Surgery International, vol. 28, no. 6, pp. 579–589, 2012. View at Publisher · View at Google Scholar
  • Maria New, Heidi Olzscha, and Nicholas B. La Thangue, “HDAC inhibitor-based therapies: Can we interpret the code?,” Molecular Oncology, vol. 6, no. 6, pp. 637–656, 2012. View at Publisher · View at Google Scholar
  • James J. Driscoll, and Roopa De Chowdhury, “Molecular crosstalk between the proteasome, aggresomes and autophagy: Translational potential and clinical implications,” Cancer Letters, vol. 325, no. 2, pp. 147–154, 2012. View at Publisher · View at Google Scholar
  • Min Xie, and Joseph A. Hill, “HDAC-dependent ventricular remodeling,” Trends in Cardiovascular Medicine, vol. 23, no. 6, pp. 229–235, 2013. View at Publisher · View at Google Scholar
  • Banzhou Pan, Jun Yi, and Haizhu Song, “MicroRNA-Mediated Autophagic Signaling Networks and Cancer Chemoresistance,” Cancer Biotherapy & Radiopharmaceuticals, pp. 130710073637009, 2013. View at Publisher · View at Google Scholar
  • Zhong-Hua Li, Xiao-Bing Zhang, Xi-Qian Han, Cong-Ran Feng, Feng-Shan Wang, Peng George Wang, Jie Shen, and Yi-Kang Shi, “Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer,” Oncology Reports, vol. 30, no. 1, pp. 499–505, 2013. View at Publisher · View at Google Scholar
  • Eun-Sun Choi, Gyoonhee Han, Song-Kyu Park, Kiho Lee, Hyun-Jung Kim, Sung-Dae Cho, and Hwan Mook Kim, “A248, a novel synthetic HDAC inhibitor, induces apoptosis through the inhibition of specificity protein 1 and its downstream proteins in human prostate cancer cells,” Molecular Medicine Reports, vol. 8, no. 1, pp. 195–200, 2013. View at Publisher · View at Google Scholar
  • Ágnes Bánréti, Miklós Sass, and Yacine Graba, “The emerging role of acetylation in the regulation of autophagy,” Autophagy, vol. 9, no. 6, pp. 819–829, 2013. View at Publisher · View at Google Scholar
  • Rajak, Singh, Dewangan, Patel, Jain, Tiwari, Veerasamy, and Sharma, “Peptide based macrocycles: Selective histone deacetylase inhibitors with antiproliferative activity,” Current Medicinal Chemistry, vol. 20, no. 14, pp. 1887–1903, 2013. View at Publisher · View at Google Scholar
  • Christine Walko, Jai Patel, Billie M. Moats-Staats, Andrew McFadden, Scott V. Smith, Wasiuddin A. Khan, Arlene S. Bridges, Allison M. Deal, Javier Oesterheld, Ian J. Davis, Julie Blatt, and Don W. Coulter, “Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors,” Anti-Cancer Drugs, vol. 24, no. 4, pp. 415–421, 2013. View at Publisher · View at Google Scholar
  • Y Zhu, K Das, J Wu, M H Lee, and P Tan, “RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells,” Oncogene, 2013. View at Publisher · View at Google Scholar
  • E. Yu. Kochetkova, T. V. Bykova, S. G. Zubova, and T. V. Pospelova, “Involvement of MAP-kinase cascades in regulation of sodium-butyrate-induced premature senescence,” Cell and Tissue Biology, vol. 7, no. 2, pp. 126–135, 2013. View at Publisher · View at Google Scholar
  • Y J Kim, C B Greer, K R Cecchini, L N Harris, D P Tuck, and T H Kim, “HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade,” Oncogene, vol. 32, no. 23, pp. 2828–2835, 2013. View at Publisher · View at Google Scholar
  • Katherine Ververis, Alison Hiong, Tom C Karagiannis, and Paulv V. Licciardi, “Histone deacetylase inhibitors (HDACIS): Multitargeted anticancer agents,” Biologics: Targets and Therapy, vol. 7, no. 1, pp. 47–60, 2013. View at Publisher · View at Google Scholar
  • Bo Ram Han, Bo Ra You, and Woo Hyun Park, “Valproic acid inhibits the growth of HeLa cervical cancer cells via caspase-dependent apoptosis,” Oncology Reports, vol. 30, no. 6, pp. 2999–3005, 2013. View at Publisher · View at Google Scholar
  • Savita Bhallar, Andrew M. Evens, Sheila Prachandl, Paul T. Schumacker, and Leo I. Gordon, “Paradoxical Regulation of Hypoxia Inducible Factor-1 alpha (HIF-1 alpha) by Histone Deacetylase Inhibitor in Diffuse Large B-Cell Lymphoma,” Plos One, vol. 8, no. 11, 2013. View at Publisher · View at Google Scholar
  • Jianzhou Cui, and Han-Ming Shenpp. 175–203, 2013. View at Publisher · View at Google Scholar
  • Usman Sumo Friend Tambunan, Ridla Bakri, Tirtana Prasetia, Arli Aditya Parikesit, and Djati Kerami, “Molecular dynamics simulation of complex Histones Deacetylase (HDAC) Class II Homo Sapiens with suberoylanilide hydroxamic acid (SAHA) and its derivatives as inhibitors of cervical cancer.,” Bioinformation, vol. 9, no. 13, pp. 696–700, 2013. View at Publisher · View at Google Scholar
  • Ruethairat Sriraks, and Temduang Limpaiboon, “Histone deacetylases and their inhibitors as potential therapeutic drugs for cholangiocarcinoma -cell line findings,” Asian Pacific Journal of Cancer Prevention, vol. 14, no. 4, pp. 2503–2508, 2013. View at Publisher · View at Google Scholar
  • Michele Cea, Antonia Cagnetta, Marco Gobbi, Paul G. Richardson, Teru Hideshima, Kenneth C. Anderson, and Franco Patrone, “New insights into the treatment of multiple myeloma with histone deacetylase inhibitors,” Current Pharmaceutical Design, vol. 19, no. 4, pp. 734–744, 2013. View at Publisher · View at Google Scholar
  • Jing Zhang, and Qing Zhong, “Histone deacetylase inhibitors and cell death,” Cellular and Molecular Life Sciences, 2014. View at Publisher · View at Google Scholar
  • Xiaodong Jin, Yan Liu, Fei Ye, Xiongxiong Liu, Yoshiya Furusawa, Qingfeng Wu, Feifei Li, Xiaogang Zheng, Zhongying Dai, and Qiang Li, “Role of autophagy in high linear energy transfer radiation-induced cytotoxicity to tumor cells,” Cancer Science, 2014. View at Publisher · View at Google Scholar
  • Xinmiao Yang, Ning Zhang, Zeliang Shi, Zhangyu Yang, and Xichun Hu, “Histone deacetylase inhibitor suberoyl bis-hydroxamic acid suppresses cell proliferation and induces apoptosis in breast cancer cells,” Molecular Medicine Reports, 2014. View at Publisher · View at Google Scholar
  • Olivia S. Chao, and Oscar B. Goodman, “Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP,” Molecular Cancer Research, vol. 12, no. 12, pp. 1755–1766, 2014. View at Publisher · View at Google Scholar
  • Ahmed Sawas, and Owen A O’Connor, “Belinostat for the treatment of T-cell lymphoma,” Expert Opinion on Orphan Drugs, pp. 1–9, 2014. View at Publisher · View at Google Scholar
  • Tae-Gul Lee, Eun-Hui Jeong, Seo Yun Kim, Hye-Ryoun Kim, and Cheol Hyeon Kim, “The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFRT790M-mutated lung cancer,” International Journal of Cancer, 2014. View at Publisher · View at Google Scholar
  • Huilai Zhang, Huijuan Lv, and Huaqing Wang, “Mechanisms of histone deacetylase inhibitor in treating T-cell lymphoma and related clinical trials,” Chinese Journal of Clinical Oncology, vol. 41, no. 19, pp. 1213–1216, 2014. View at Publisher · View at Google Scholar
  • V El-Khoury, S Pierson, E Szwarcbart, N H C Brons, O Roland, S Cherrier-De Wilde, L Plawny, E Van Dyck, and G Berchem, “Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia,” Leukemia, 2014. View at Publisher · View at Google Scholar
  • Yun-feng Qi, Yan-xin Huang, Yan Dong, Li-hua Zheng, Yong-li Bao, Lu-guo Sun, Yin Wu, Chun-lei Yu, Hong-yu Jiang, and Yu-xin Li, “Systematic Analysis of Time-Series Gene Expression Data on Tumor Cell-Selective Apoptotic Responses to HDAC Inhibitors,” Computational and Mathematical Methods in Medicine, vol. 2014, pp. 1–15, 2014. View at Publisher · View at Google Scholar
  • Li-Ting Wen, Jie Wang, Ye Wang, and Fu-Quan Chen, “Association between histone deacetylases and the loss of cochlear hair cells: Role of the former in noise-induced hearing loss,” International Journal of Molecular Medicine, vol. 36, no. 2, pp. 534–540, 2015. View at Publisher · View at Google Scholar
  • Aditya Kumar Bubna, “Vorinostat-An overview,” Indian Journal of Dermatology, vol. 60, no. 4, pp. 419, 2015. View at Publisher · View at Google Scholar
  • Prabhat Singh, Raghuvir Singh Tomar, and Srikanta Kumar Rath, “Anticancer potential of the histone deacetylase inhibitor-like effects of flavones, a subclass of polyphenolic compounds: a review,” Molecular Biology Reports, 2015. View at Publisher · View at Google Scholar
  • Po-Hao Feng, Ya-Li Huang, Kai-Jen Chuang, Kuan-Yuan Chen, Kang-Yun Lee, Shu-Chuan Ho, Mauo-Ying Bien, You-Lan Yang, and Hsiao-Chi Chuang, “Dysfunction of methionine sulfoxide reductases to repair damaged proteins by nickel nanoparticles,” Chemico-Biological Interactions, 2015. View at Publisher · View at Google Scholar
  • Pospelova, Gordeev, Bykova, Zubova, and Aksenov, “The antiapoptotic gene bcl-2 prevents reactivation of the senescence program induced by the histone deacetylase inhibitor sodium butyrate in rat fibroblasts transformed by the oncogenes E1A and c-Ha-Ras,” Cell and Tissue Biology, vol. 9, no. 3, pp. 182–190, 2015. View at Publisher · View at Google Scholar
  • Somprasong Khaopha, Sanun Jogloy, Aran Patanothai, and Thanaset Senawong, “Histone Deacetylase Inhibitory Activity of Peanut Testa Extracts against Human Cancer Cell Lines,” Journal of Food Biochemistry, 2015. View at Publisher · View at Google Scholar
  • Mee-Young Ahn, Ji-Wee Ahn, Hyung-Sik Kim, Jun Lee, and Jung-Hoon Yoon, “Apicidin inhibits cell growth by downregulating IGF-1R in salivary mucoepidermoid carcinoma cells,” Oncology Reports, 2015. View at Publisher · View at Google Scholar
  • Yongxia Zheng, Huan Chen, Manxiang Yin, Xiaoqian Ye, Guiqian Chen, Xinmei Zhou, Lei Yin, Chengwen Zhang, and Baoyue Ding, “MiR-376a and histone deacetylation 9 form a regulatory circuitry in hepatocellular carcinoma,” Cellular Physiology and Biochemistry, vol. 35, no. 2, pp. 729–739, 2015. View at Publisher · View at Google Scholar
  • Thanaset Senawong, Paweena Wongphakham, Thussanee Saiwichai, Chanokbhorn Phaosiri, and Pakit Kumboonma, “Histone deacetylase inhibitory activity of hydroxycapsaicin, a synthetic derivative of capsaicin, and its cytotoxic effects against human colon cancer,” Turkish Journal Of Biology, vol. 39, no. 3, pp. 370–379, 2015. View at Publisher · View at Google Scholar
  • Xi-Feng Zhang, Qi Yan, Wei Shen, and Sangiliyandi Gurunathan, “Trichostatin A Enhances the Apoptotic Potential of Palladium Nanoparticles in Human Cervical Cancer Cells,” International Journal of Molecular Sciences, vol. 17, no. 8, pp. 1354, 2016. View at Publisher · View at Google Scholar
  • Marisela Agudelo, Gloria Figueroa, Tiyash Parira, Adriana Yndart, Karla Munoz, Venkata Atluri, Thangavel Samikkannu, and Madhavan P. Nair, “Profile of Class I Histone Deacetylases (HDAC) by Human Dendritic Cells after Alcohol Consumption and In Vitro Alcohol Treatment and Their Implication,” Plos One, vol. 11, no. 6, 2016. View at Publisher · View at Google Scholar
  • Susmitha Apuri, and Lubomir Sokol, “An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin’s lymphoma,” Expert Opinion on Investigational Drugs, pp. 1–10, 2016. View at Publisher · View at Google Scholar
  • Min Xie, and Joseph A. Hill, “Cardiac Autophagy and Its Regulation by Reversible Protein Acetylation,” Epigenetics in Cardiac Disease, pp. 231–262, 2016. View at Publisher · View at Google Scholar
  • Qi Shen, Yan Yang, Ya-Wei Qian, Jian Zhang, Jun-Chuang He, Tao Yang, Wei Yao, Jian-Ming Wang, Peter Schemmer, Yan Liu, and Wei-Peng Qi, “TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors,” Oncotarget, vol. 7, no. 46, pp. 75441–75456, 2016. View at Publisher · View at Google Scholar
  • Sukanya Shyamasundar, S. Thameem Dheen, and B. Huat Bay, “Histone Modifications as Molecular Targets in Nasopharyngeal Cancer,” Current Medicinal Chemistry, vol. 23, no. 2, pp. 186–197, 2016. View at Publisher · View at Google Scholar
  • Marek Pieszka, Paulina Szczurek, Katarzyna Ropka-Molik, Maria Oczkowicz, and Magdalena Pieszka, “The role of resveratrol in the regulation of cell metabolism - A review,” Postepy Higieny i Medycyny Doswiadczalnej, vol. 70, pp. 117–123, 2016. View at Publisher · View at Google Scholar
  • Jin Li, Changgeng Qian, Qianqian Zhou, Jiwei Li, Kunlun Li, and Pingyong Yi, “BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma,” Biochemical and Biophysical Research Communications, 2017. View at Publisher · View at Google Scholar
  • Anne Bergougnoux, Magali Taulan-Cadars, Arnaud Bourdin, Aurélie Petit, Lucie Knabe, Estelle Bribes, Raphaël Chiron, Albertina De Sario, Mireille Claustres, Nicolas Molinari, and Isabelle Vachier, “The HDAC inhibitor SAHA does not rescue CFTR membrane expression in Cystic Fibrosis,” International Journal of Biochemistry and Cell Biology, vol. 88, pp. 124–132, 2017. View at Publisher · View at Google Scholar
  • Jai-Sing Yang, Chi-Cheng Lu, Sheng-Chu Kuo, Yuan-Man Hsu, Shih-Chang Tsai, Shih-Yin Chen, Yng-Tay Chen, Ying-Ju Lin, Yu-Chuen Huang, Chao-Jung Chen, Wei-De Lin, Wen-Lin Liao, Wei-Yong Lin, Yu-Huei Liu, Jinn-Chyuan Sheu, and Fuu-Jen Tsai, “Autophagy and its link to type II diabetes mellitus,” BioMedicine, vol. 7, no. 2, pp. 8, 2017. View at Publisher · View at Google Scholar
  • Maria Saveria Gilardini Montani, Marisa Granato, Claudio Santoni, Paola Del Porto, Nicolò Merendino, Gabriella D’Orazi, Alberto Faggioni, and Mara Cirone, “Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells,” Cellular Oncology, vol. 40, no. 2, pp. 167–180, 2017. View at Publisher · View at Google Scholar
  • Shinichi Uesato, Tsutomu Sasaki, and Yoshiyuki Hirata, “Potential application of 5-aryl-substituted 2-aminobenzamide type of HDAC1/2-selective inhibitors to pharmaceuticals,” Current Pharmaceutical Design, vol. 23, no. 40, pp. 6149–6159, 2017. View at Publisher · View at Google Scholar
  • Shiqi Li, Kin-Sang Cho, Na Liu, and Nan Wu, “Acetylation and deacetylation in cancer stem-like cells,” Oncotarget, vol. 8, no. 51, pp. 89315–89325, 2017. View at Publisher · View at Google Scholar
  • Mee-Young Ahn, “HDAC inhibitor apicidin suppresses murine oral squamous cell carcinoma cell growth in vitro and in vivo via inhibiting HDAC8 expression,” Oncology Letters, vol. 16, no. 5, pp. 6552–6560, 2018. View at Publisher · View at Google Scholar
  • Wei Du, Na Wang, Fan Li, Keqi Jia, Jiahui An, Yaping Liu, Yuxue Wang, Lin Zhu, Song Zhao, and Jun Hao, “STAT3 phosphorylation mediates high glucose–impaired cell autophagy in an HDAC1-dependent and -independent manner in Schwann cells of diabetic peripheral neuropathy,” The FASEB Journal, vol. 33, no. 7, pp. 8008–8021, 2019. View at Publisher · View at Google Scholar
  • Shotaro Eto, Kohei Saeki, Ryohei Yoshitake, Sho Yoshimoto, Masahiro Shinada, Namiko Ikeda, Satoshi Kamoto, Yuiko Tanaka, Daiki Kato, Shingo Maeda, Masaya Tsuboi, James Chambers, Kazuyuki Uchida, Ryohei Nishimura, and Takayuki Nakagawa, “Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells,” Plos One, vol. 14, no. 6, pp. e0218382, 2019. View at Publisher · View at Google Scholar
  • Michael E. Taylor, Melissa Hadley, Satish Noonepalle, Debarati Banik, and Alejandro Villagra, “Functional Analysis of HDACs in Tumorigenesis,” Partial Differential Equations I, vol. 115, pp. 279–307, 2019. View at Publisher · View at Google Scholar
  • Min-Hyun Baek, Jeong-Yeol Park, Yangsoon Park, Kyu-Rae Kim, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, and Joo-Hyun Nam, “The combination of histone deacetylase and p53 expressions and histological subtype has prognostic implication in uterine leiomyosarcoma,” Japanese Journal of Clinical Oncology, 2019. View at Publisher · View at Google Scholar
  • Yong Ling, Wei-Jie Gao, Changchun Ling, Ji Liu, Chi Meng, Jianqiang Qian, Siqun Liu, Huiling Gan, Hongmei Wu, Jinhua Tao, Hong Dai, and Yanan Zhang, “β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma,” European Journal of Medicinal Chemistry, 2019. View at Publisher · View at Google Scholar
  • Nikolaos Garmpis, Christos Damaskos, Anna Garmpi, Serena Valsami, and Dimitrios Dimitroulis, “Pharmacoepigenetics of Histone Deacetylase Inhibitors in Cancer,” Pharmacoepigenetics, pp. 501–521, 2019. View at Publisher · View at Google Scholar